$FOCL

WILLSEY LANCE purchased $238K of FOCL

WILLSEY LANCE purchased 50,000 shares of EDAP TMS SA (FOCL) at $4.75 ($0.24M total) on 2026-08-14.

Original reporting
SEC EDGAR · WILLSEY LANCE
Published Aug 17, 2026, 10:01 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FOCL
Bullish
low confidence
Mentioned
$FOCL
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FOCLBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 50,000 shares at a stated price, which may slightly influence sentiment but does not change company fundamentals in the provided text.

02

Market read

Traders may note the insider buying as a small positive sentiment datapoint, but there is no new operational or financial information here.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but the article provides no context on prior holdings, intent, or whether other insiders acted.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction disclosure for EDAP TMS SA (FOCL).

Company-level read

Ticker impact

$FOCLBullishLow confidence
Context

Form 4 shows director WILLSEY LANCE bought 50,000 shares of FOCL at $4.7500 on 2026-08-14, totaling $237,500.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a routine insider transaction with no accompanying guidance, deal, or operational change disclosed in the text.

Market effects

No sector-wide implications are stated.

None indicated.

None indicated.

Counterpoint

Insider purchases can be discretionary, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • EDAP TMS SA

    Company whose shares (FOCL) were purchased by a director per the Form 4.

  • WILLSEY LANCE

    Director who reported an open-market purchase of 50,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

$FOCLMed

FocalTherics Q2 Earnings Call Highlights

FocalTherics (NASDAQ:FOCL) reported Q2 highlights from its earnings call. U.S. Focal One procedure volumes rose 47% YoY. HIFU gross margin increased to 55.6% from 51.1%. Cash was $21.5M and it drew about €14M under its EIB credit facility. The company plans a $40M Aug. 14 offering and reiterated 2026 HIFU revenue guidance of $50M to $54M.

$FOCLMedAI 8/10

FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M

FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial resul

$FOCLMed

FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down

FocalTherics (FOCL) reported preliminary unaudited Q2 2026 results. Revenue is expected at $12.7 to $13.2 million, up 34% to 39% from $9.7 million in Q2 2025, with gross margin at 54% to 56% versus 42.5%. Cash and investments were $21.5 million as of June 30. The company priced a public offering of 8.425M ADS at $4.75 to raise about $40M gross, with an option for 1.26375M more ADS.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com